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1. Introduction 
Among the macrolide antibiotics, azithromycin has the longest biological half-life because of its high volume of 
distribution, where tissue concentrations are much higher than blood levels.  High concentrations are taken up into white 
blood cells and, therefore, plasma concentrations are of little value as a guide to efficacy [1].  A 500 mg daily dose for 3 
days is optimum for patient compliance in the eradication of mostly respiratory tract infections without the inconvenience 
of multiple daily dosing with other antibiotics.  Several off-patent azithromycin dihydrate 500 mg tablet formulations have 
proliferated the Philippines market.  Most of these products are sold at highly cheaper retail prices than the innovator 
product, making their qualities, safety and efficacy oblivious to scrutiny among physicians and pharmacists.  To ensure 
safety and efficacy of generic products, the conduct of expensive bio-equivalence studies using human subjects are 
preferred because actual pharmacokinetic data are compared against the innovator product.  A cheaper alternative is the 
conduct of in vitro comparative multipoint dissolution studies as they correlate well with in vivo bio-equivalence studies 
[2]. This study compares the multi-point dissolution profiles of 3 off-patent azithromycin dihydrate 500 mg tablets currently 
available in the Philippines against the innovator product.     
 
2. Materials and Methods 
2.1. Product Procurement  
Samples of azithromycin dihydrate 500 mg tables were provided either as gifts or were purchased at wholesale 
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price from medical representatives on the condition that the samples have a remaining shelf-life of at least 18 months at the 
time they were donated or purchased.  These are as follows: 
a. Pfizer, Inc., Makati, Philippines (ZithromaxTM, designated as the innovator product with lot no. B141464102 and expiring 
on April 30, 2017); 
b. Farma Iberica Co., Pasig City, Philippines (OD MacTM, designated as test sample 1, with lot no. EMM401 and expiring 
on September 30, 2016); 
c. Stallion Lab., Gujarat, India (AnzalTM, designated as test sample 2 with lot no. PH240 and expiring on October 31, 2016); 
and 
d. Interphil Lab., Cabuyao, Laguna, Philippines (ZithramycinTM, designated as test sample 3 with lot no. 14ZAT-1 and 
expiring on August 2016).  
 
2.2. Dissolution Testing 
Each of the 6 vessels of the USP dissolution type 2 apparatus was filled with 900 mL of 0.1-N HCl.  One tablet 
coming from any of the 3 test samples and the innovator product were randomly distributed into each vessel and the 
paddles were made to rotate at 75 rpm.  From each vessel, 2 mL aliquot portion was taken at the end of 5, 10, 20, 30, 40, 
60, 80 and 120 minutes and then filtered (Millipore No. 1).  The filtrates were diluted to 100 ml with 0.1-N HCl and then 
assayed for azithromycin dihydrate content. Two mL of fresh medium was replaced after each aliquot withdrawal to 
maintain sink conditions.  More cycles of dissolution tests were repeated similarly so that at the end of the study, 6 units of 
each of the 3 test sample and the innovator product have been subjected to multi-point dissolution testing.     
2.3. Assay for Azithromycin Dihydrate by High-performance Liquid Chromatography (HPLC) 
Azithromycin dihydrate reference standard was dissolved in 0.1-N HCl and then filtrered (Millipore no. 1) to 
produce a 0.1 mg/mL standard solution.  The standard solution and the finally diluted test sample solutions from 2.2 were 
injected at 20-µL quantities in a Merck Hitachi 24-1 (Tokyo, Japan) equipped with a reverse phase C-18 column (5 x 4.66 
mm) that was heated at 50
0
C and a UV detector at 210 nm and eluted with HPLC grade 0.03-M phosphate buffer – 
methanol (20:80 v/v, pH = 7.5; Merck Co.) at a flow rate of 2 mL/minute [3].   
2.4. Quality Control of the Materials Procured 
The 3 test samples and innovator products were tested for assay for azithromycin dihydrate content by the 
spectrophotometric method  of Patil et al [4] (2011), friability (Roche ED-2), hardness, (Stokes-Monsanto),  disintegration 
(USP Electrolab) in 0.1-N HCl for 2 hours at 37 ± 2
0
C and weight variation (Sartorius PG 03-S).   
 
3. Results and Discussions 
3.1. Comparative Multi-point Dissolution Profiles 
The area under the dissolution-time curves for the 3 test samples were compared against the innovator product by 
the similarity (f2) and difference (f1) factors, such that f2 = 50log [{1 + 1/n Σ (Rt – Tt )
2
}
-0.5
 x 100 and f1 = [{ Σ ǀ Rt – Tt ǀ / Σ 
Rt} x 100], where Rt and Tt  are the percentage drug dissolved at each time point for the innovator and test products, 
respectively, n is the number of dissolution sampling time and t are the time points for collecting dissolution samples.  
Figure I compares the dissolution-time curve of the 3 test samples and the innovator product.   
Figure 1:  Comparative Multi-point Dissolution between the Three Test Samples and the Innovator 
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The dissolution-time curve of test sample 3 was comparable to the innovator product, assuming almost mirro-
image super imposable dimensions.  Test sample 2 failed to achieve this, with Q values being significantly lower than the 
innovator product and the 2 other test samples after 30 minutes.  Test sample 1 gave significantly higher Q values than the 
innovator starting at 40 minutes. All 4 products exhibited an initial phase of high release (i.e., burst effect) with a common 
asymptote after 40 minutes, followed by a second phase of moderate release.  To validate this finding, comparison of f1 and 
f2 values were made and are presented in Table I.   
Table I:  Comparative Similarity and Difference Factors Among the Three Test Products 
Formulations Similarity (f2) Difference (f1) 
Test Sample 1 51.16% 8.88% 
Test Sample 2 51.99% 28.90% 
Test Sample 3 53.00% 3.01% 
*p < 0.001 vs. innovator up to 120 mins. 
**p < 0.05 vs. innovator up to 120 mins. 
 
 All 3 test samples passed the Food and Drug Authority (FDA) specification for f2 which should be at least 50% to 
make it equivalent to the innovator product in terms of comparative in vivo multi-point dissolution.  However, test sample 2 
exceeded the maximum f1 value of 15% set by the FDA and that does not make it equivalent to the innovator product as far 
as in vitro bio-equivalence is concerned. 
3.2. Kinetics of Dissolution 
To analyze the in vitro dissolution release of azithromycin dihydrate, the following kinetic models were applied: 
a. Zero order, where cumulative concentration Q was plotted against time t;  
b. First order, where log Q was plotted against t;  
c. Higuchi  model where Q was plotted against square root of time t;   
d. Hixson-Crowell, where Mo1/3 – Mt1/3 = KHCt, such that Mt is the amount of drug released in time t and Mo is the initial 
amount of the drug in the sample (~ 500 mg), and where Mo
1/3
 –  
                Mt
1/3  
was plotted against t; and 
e. Korsmeyer-Peppa, where log Q, up to 60%, was plotted against log time t.   
 Information on the dissolution kinetics of the 3 test samples and the innovator product are provided in Table II.  
The plots of azithromycin dihydrate with zero order, first order and Hixson-Crowell kinetics showed low linearity, were r < 
0.9 for zero order and r < 0.8 for first order and Hixson-Crowell kinetics, to signify that diffusion is independent of 
concentrations.  The best linearity was found with Higuchi’s and Korsmeyer-Peppa's kinetics (r > 0.9).    
Table II: Comparative Dissolution Release Kinetics 
Formulation Drug Release Kinetics (r = correlation coefficient) 
Zero Order First Order Higuchi Hixson-Crowell Korsmeyer – Peppa 
r r r r r n 
Test Sample 1 0.82 0.64 0.91 -0.77 0.99 1.06 
Test Sample 2 0.88 0.77 0.96 -0.81 0.99 0.93 
Test Sample 3 0.81 0.72 0.91 -0.63 0.98 1.1 
Innovator 0.82 0.72 0.92 -0.76 0.98 1.1 
 
 The Higuchi plots, shown in Figure II, assumes one-dimensional drug diffusion where matrix swelling and 
dissolution are negligible within a perfect sink condition [2].  It is apparent that after 30 minutes, the Higuchi plots of test 
sample 2 was not comparable to the innovator product and test samples 1 and 3.  The Korsmeyer-Peppa model was 
designed to to confirm whether release mechanisms of drugs from cylindrical tables obey Ficks' law of diffusion.  The 
release exponent n, which is derived from the slope of he Korsmeyer-Peppa plots in Figure III, characterizes different 
release mechanisms described in Table III [2]. All 3 test samples and the innovator product gave n values higher than 0.89 
which means that these products follow super case II transport diffusion due to chain entanglement as a result of swelling of 
hydrophobic and hydrophilic polymers which are present in the formulations to provide sustained-release properties [5].    
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Figure II: Comparative Higuchi Plots of the Various Samples Tested 
 
 
Figure III: Comparative Korsmeyer-Peppa's Plots of the Various Samples Tested 
 
 
Table III: Interpretation of Diffusional Release Mechanisms from Polymeric Films 
Release Exponent n Drug Transport Mechanism Rate as a Function of Time 
0.5 Fickian diffusion t 
-0.5
 
0.45 < n = 0.89 Non-Fickian transport t 
n-1
 
0.89 Case II transport Zero order release 
Higher than 0.89 Super Case II transport t 
n-1
 
 
3.3. Quality Control of the Finish Products 
Table IV compares the 3 test samples against the innovator product based on standard quality control tests for 
tablets.  Results showed that there are no appreciable differences among the 3 test samples and the innovator product in 
terms of disintegraion and weight variation tests.  However, test sample 2 exceeded the friability limit of 1%, making it 
oblivious to abrasion during transport.  Test sample 2 is the hardest among the samples tested at almost 7 kg, a factor that 
reflects the high amount of binders in the formulation.  Too much abrasion and the additive effects of excessive amount of 
binders are factors to consider why test sample 2 was not equivalent with the innovator product, let alone test samples 1 and 
3.  Furthermore, it is possible that the overage of 3.2% observed with test sample 1 after assay for azithromycin dihydrate 
content contributed to the high Q values during dissolution as reflected in Figures 1 and 2.  This overage, however, is still 
deemed acceptable as the upper monograph limit is set at 110% by the United States Pharmacopoeia 34. 
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Table IV:  Quality Control Tests for the Various Samples Tested 
Formulation 
(N = 20) 
Mean ± S.E.M. (Specification) 
Assay  Friability Hardness Disintegraton Weight Variation 
Test Sample 1 103.20 ± 0.32% 0.23 ± 0.02% 4.7 ± 0.21 kg 6.2 ± 0.23 mins. 777.2 ± 4.5 mg 
Test Sample 2 98.80 ± 0.17% 1.11 ± 0.03% 6.8 ± 0.11 kg 6.1 ± 0.19 mins. 713.5 ± 5.6 mg 
Test Sample 3 99.30 ± 0.21% 0.46 ± 0.01% 4.2 ± 0.02 kg 5.7 ± 0.13 mins. 792.3 ± 4.8 mg 
Innovator 100.30 ± 0.13% 0.25 ± 0.03% 4.4 ± 0.12 kg 5.9 ± 0.14 mins. 788.3 ± 5.8 mg 
 
4. Discussions 
Cost analysis and survey of the azithromycin dihydrate 500 mg tablets tested in this study showed the following 
retail prices:  test sample 2 (Anzal
TM
) at 60 pesos per 500 mg tablet; test sample 3 (Zithramycin
TM
) at 40 pesos per tablet; 
test sample 1 (OD MAC
TM
) at 140 pesos per tablet; and the innovator (Zithromax
TM
) at 151.25 pesos per tablet.  This study 
showed that generic branding at relatively cheaper prices than the innovator is possible by formulating preparations that are 
bio-equivalent through comparative in vivo multi-point dissolution testing.  This study revealed that test samples 1 and 3 are 
comparable with the innovator product in terms of similarity and difference factors and exhibited similar extra-Fickian 
diffusion behavior as both fitted to Higuchi and Korsmeyer-Peppa release kinetics.  These findings are important since 
azithromycin dihydrate has a relatively long shelf-life and high volume of distribution as it is primarily stored in tissues so 
that it is important that their tablet preparations provide sustained-release mechanisms to maintain patient compliance, 
particularly when these tablets are given once daily for 3 days [6]. 
It was found out that test sample 2 was not equivalent to the innovator in terms of multi-point comparative in vitro 
dissolution testing but these findings do not translate to poor quality in terms of bioavailability, even if it also failed 
friability and hardness tests.  It has passed assay limits and, therefore, it should release azithromycin into the blood streams 
and underlying tissues at sufficient bactericidal concentrations [7].  
 
5. Conclusions 
This study showed that 2 of the 3 off-patent generic azithromycin dihydrate 500 mg tablets are equivalent to the 
innovator product in terms of multi-point in vitro dissolution profile.  All 3 preparations tested exhibited extra-Fickian 
release mechanisms that are characteristics of drugs released from matrices that constains hydrolloidal polymers that are 
intended to provide sustained-release effects. 
  
References 
[1] Wilms, E.B., Touw, D.J. and Heijerman, H.G.M. Pharmacokinetics and sputum penetration of azithromycin during 
once weekly dosing in cystic fibrosis patients. J. Cystick Fibrosis, 2008; 7 (1): 79-84.  
[2] Dash, S., Murthy, P.N., Nath, L. and Chowdhury.  Kinetic modeling on drug release from  controlled drug delivery 
systems.  P.  Acta Pol. Phar. Drug Res., 2010; 67 (3): 217-223 
[3] Al-Rhimawi, F. and Khaoaf, M.  Analysis of azithromycin and its related compounds by RP- HPLC with UV Detection.  
J. Chrom. Sci., 2010; 48 (2): 86-90. 
[4] Patil, A., Payghan, S and Disouza J.  Formulation and evaluation of enteric-coated tablets of  azithromycin dihydrate. 
Int. J. ChemTech Res., 2011; 3 (3): 1479-1484.  
[5] Althaf, A.S., Seshadri,T., Sivakranth, M. et al. Design and study of lamivudine oral sustained release tablets.  Pelagia 
Res. Lib. 2010; 1 (2): 61-76. 
[6] Sun, L., Zhang, W., Liu, X. et al. Preparation and evaluation of sustained-release azithromycin tablets in vitro and in 
vivo.  Asian J. Phar. Sci., 2014; 9 (3):  155-161. 
[7] Christopher, J.D.and Barradel, L.B. Azithromycin:  a review of its pharmacological properties and use as a 3-day 
therapy in respiratory tract infections.  Drugs, 1996; 51:  483-505. 
 
